- Record: found
- Abstract: not found
- Article: not found
Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
Jeanne Tie ,
Yuxuan Wang ,
Cristian Tomasetti ,
Lu Li ,
Simeon Springer ,
Isaac Kinde ,
Natalie Silliman ,
Mark Tacey ,
Hui-Li Wong ,
Michael Christie ,
Suzanne Kosmider ,
Iain Skinner ,
Rachel Wong ,
Malcolm Steel ,
Ben Tran ,
Jayesh Desai ,
Ian Jones ,
Andrew Haydon ,
Theresa Hayes ,
Tim J. Price ,
Robert L. Strausberg ,
Luis A. Diaz ,
Nickolas Papadopoulos ,
Kenneth W. Kinzler ,
Bert Vogelstein ,
Peter Gibbs
July 06 2016
July 06 2016
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
<p class="first" id="P1">Detection of circulating tumor DNA (ctDNA) after resection
of stage II colon cancer
may identify patients at the highest risk of recurrence and help inform adjuvant treatment
decisions. We used massively parallel sequencing–based assays to evaluate the ability
of ctDNA to detect minimal residual disease in 1046 plasma samples from a prospective
cohort of 230 patients with resected stage II colon cancer. In patients not treated
with adjuvant chemotherapy, ctDNA was detected postoperatively in 14 of 178 (7.9%)
patients, 11 (79%) of whom had recurred at a median follow-up of 27 months; recurrence
occurred in only 16 (9.8 %) of 164 patients with negative ctDNA [hazard ratio (HR),
18; 95% confidence interval (CI), 7.9 to 40;
<i>P</i> < 0.001]. In patients treated with chemotherapy, the presence of ctDNA
after completion
of chemotherapy was also associated with an inferior recurrence-free survival (HR,
11; 95% CI, 1.8 to 68;
<i>P</i> = 0.001). ctDNA detection after stage II colon cancer resection provides
direct evidence
of residual disease and identifies patients at very high risk of recurrence.
</p>